Showing 1 - 18 results of 18 for search '"Molecular Oncology"', query time: 0.04s Refine Results
  1. 1
    Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA

    Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA by Martin Metzenmacher, Gregor Zaun, Marija Trajkovic‐Arsic, Phyllis Cheung, Timm M. Reissig, Hendrik Schürmann, Nils vonNeuhoff, Grainne O'Kane, Stephanie Ramotar, Anna Dodd, Steven Gallinger, Alexander Muckenhuber, Jennifer J. Knox, Volker Kunzmann, Peter A. Horn, Jörg D. Hoheisel, Jens T. Siveke, Smiths S. Lueong

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening

    KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening by Constanza Tapia Contreras, Jonas Dominik Falke, Dana‐Magdalena Seifert, Carolin Schneider, Lukas Krauß, Xin Fang, Denise Müller, Engin Demirdizen, Melanie Spitzner, Tiago De Oliveira, Christian Schneeweis, Jochen Gaedcke, Silke Kaulfuß, Kimia Mirzakhani, Bernd Wollnik, Karly Conrads, Tim Beißbarth, Gabriela Salinas, Jonas Hügel, Nils Beyer, Sophia Rheinländer, Ulrich Sax, Matthias Wirth, Lena‐Christin Conradi, Maximilian Reichert, Volker Ellenrieder, Philipp Ströbel, Michael Ghadimi, Marian Grade, Dieter Saur, Elisabeth Hessmann, Günter Schneider

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L1

    Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L1 by Yanhong Zhang, Changli Yue, Anna M. Krichevsky, Igor Garkavtsev

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study

    Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study by Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel, Thomas Mika, Roland Schroers, Swantje Held, Kathrin Heinrich, David Tougeron, Dominik P. Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Müller, Christof Burkart, Sebastian Stintzing, Volker Heinemann

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation

    Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation by Kimberley McGrail, Elena González‐Sánchez, Paula Granado‐Martínez, Roberto Orsenigo, Yuxin Ding, Berta Ferrer, Javier Hernández‐Losa, Iván Ortega, Juan Martín‐Caballero, Eva Muñoz‐Couselo, Vicente García‐Patos, Juan A. Recio

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression

    Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression by Jasper Van Goubergen, Miroslav Peřina, Florian Handle, Elisa Morales, Anika Kremer, Oliver Schmidt, Glen Kristiansen, Marcus V. Cronauer, Frédéric R. Santer

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer

    Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer by Manoj Amrutkar, Sander Johannes Thorbjørnsen Guttorm, Anette Vefferstad Finstadsveen, Knut Jørgen Labori, Lars Eide, Helge Rootwelt, Katja Benedikte Prestø Elgstøen, Ivar P. Gladhaug, Caroline S. Verbeke

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Targeting ferroptosis for improved radiotherapy outcomes in HPV‐negative head and neck squamous cell carcinoma

    Targeting ferroptosis for improved radiotherapy outcomes in HPV‐negative head and neck squamous cell carcinoma by Joo Kyung Noh, Min Kyeong Lee, Yeonseo Lee, Minji Bae, Soonki Min, Moonkyoo Kong, Jung Woo Lee, Su Il Kim, Young Chan Lee, Seong‐Gyu Ko, Seon Rang Woo, Young‐Gyu Eun

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Viral mimicry evasion: a new role for oncogenic KRAS mutations

    Viral mimicry evasion: a new role for oncogenic KRAS mutations by Raymond Chen, Aobo He, Daniel D. De Carvalho

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer

    Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer... by Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Oncogenic mutant KRAS inhibition through oxidation at cysteine 118

    Oncogenic mutant KRAS inhibition through oxidation at cysteine 118 by Maximilian Kramer‐Drauberg, Ettore Petrini, Alessia Mira, Enrico Patrucco, Rossella Scardaci, Ilenia Savinelli, Haiyun Wang, Keying Qiao, Giovanna Carrà, Marie‐Julie Nokin, Zhiwei Zhou, Kenneth D. Westover, David Santamaria, Paolo E. Porporato, Chiara Ambrogio

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    ERK1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility

    ERK1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility by Dalia de laFuente‐Vivas, Vincenzo Cappitelli, Rocío García‐Gómez, Sara Valero‐Díaz, Camilla Amato, Javier Rodriguéz, Santiago Duro‐Sánchez, Alexander vonKriegsheim, Michael Grusch, José Lozano, Joaquín Arribas, Berta Casar, Piero Crespo

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    CT45A1‐mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell‐in‐cell structure, potentiating the progression of microsatellite instability‐high colorectal cancer

    CT45A1‐mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell‐in‐cell structure, potentiating the progression of microsatellite... by Hao‐Wei Teng, Hsiang‐Yueh Huang, Chun‐Chi Lin, Yuh‐Ching Twu, Wen‐Hao Yang, Wen‐Chun Lin, Hsin‐Yi Lan, Yen‐Yu Lin, Wei‐Lun Hwang

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives

    MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives by Michael Karin, Ju Youn Kim

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression

    Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression by Elisa Carouge, Clémence Burnichon, Martin Figeac, Shéhérazade Sebda, Nathalie Vanpouille, Audrey Vinchent, Marie‐José Truong, Martine Duterque‐Coquillaud, David Tulasne, Anne Chotteau‐Lelièvre

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2

    Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2 by Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, Makoto Koyama, Yuta Yamamoto, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Michiko Takeoka, Daisuke Komatsu, Yuji Soejima

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Detection of colorectal‐cancer‐associated bacterial taxa in fecal samples using next‐generation sequencing and 19 newly established qPCR assays

    Detection of colorectal‐cancer‐associated bacterial taxa in fecal samples using next‐generation sequencing and 19 newly established qPCR assays by Thulasika Senthakumaran, Tone M. Tannæs, Aina E. F. Moen, Stephan A. Brackmann, David Jahanlu, Trine B. Rounge, Vahid Bemanian, Hege S. Tunsjø

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

    When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer by Pietro Paolo Vitiello, Nadia Saoudi González, Alberto Bardelli

    Published 2025-02-01
    “…Molecular Oncology…”
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: